News | August 06, 2024
SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Subscribe To Our Newsletter & Stay Updated
